Psilocybin
Skeletal formula of canonical psilocybin | |
Ball-and-stick model of canonical psilocybin | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌsaɪləˈsaɪbɪn/ sy-lə-SY-bin, /ˌsɪl-/ |
| Other names | Psilocybine; Psilocibin; Psylocybin; Psilotsibin; Psilocin phosphate; Psilocin phosphate ester; O-Phosphorylpsilocin; O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine; 4-Phosphoryloxy-N,N-dimethyltryptamine; 4-PO-DMT; COMP360; COMP-360; CY-39; CY39; PSOP, Psilocybin (USAN US) |
| Dependence liability | Low[1][2][3][4][5] |
| Addiction liability | Low[1][6] |
| Routes of administration | |
| Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist[8] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Oral: 52.7 ± 20.4% (as psilocin) (n=3)[10][11][12] |
| Protein binding | 66%[13] |
| Metabolism | Liver, other tissues:[11][10][7][14] • Dephosphorylation (ALP) • Demethylation and deamination (MAO) • Oxidation (ALDH) • Glucuronidation (UGTs) |
| Metabolites | • Psilocin[11][15][7] • Psilocin-O-glucuronide[15][7] • 4-Hydroxyindole-3-acetaldehyde[15][7] • 4-Hydroxyindole-3-acetic acid (4-HIAA)[15][7] • 4-Hydroxytryptophol[15][7] |
| Onset of action | Oral: 0.5–0.8 (range 0.1–1.5) h[16][11] IV: immediate[17][18] |
| Elimination half-life | Oral (as psilocin): 2.1–4.7 h (range 1.2–18.6 h)[15][19][20] IV (as psilocin): 1.2 h (range 1.8–4.5 h)[10][2] |
| Duration of action | Oral: 4–6 h (range 3–12 h)[11][21][22] IV: 15–60 min (1–2 mg)[2][12][17][18] |
| Excretion | urine (mainly as psilocin-O-glucuronide, 2–4% as unchanged psilocin)[10][7][23] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.007.542 |
| Chemical and physical data | |
| Formula | C12H17N2O4P |
| Molar mass | 284.252 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 220–228 °C (428–442 °F) [24] |
| |
| |
| (verify) | |
Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT),[a] is a naturally occurring tryptamine alkaloid and investigational drug found in more than 200 species of mushrooms, with hallucinogenic and serotonergic effects.[22][26] Effects include euphoria, changes in perception, a distorted sense of time,[27] and perceived spiritual experiences.
Psilocin is the metabolite of psilocybin. The compound psilocybin itself is biologically inactive but quickly converted by the body to psilocin.[22] Psilocybin is transformed into psilocin by dephosphorylation mediated via phosphatase enzymes.[28][22] Psilocin is chemically related to the neurotransmitter serotonin and acts as a non-selective agonist of the serotonin receptors.[22] Activation of one serotonin receptor, the serotonin 5-HT2A receptor, is specifically responsible for the hallucinogenic effects of psilocin and other serotonergic psychedelics.[22] Psilocybin is usually taken orally.[22] By this route, its onset is about 20 to 50 minutes, peak effects occur in about 1 to 2 hours, and its duration is about 4 to 6 hours.[11][21][22][16]
Psilocybin mushrooms were used ritualistically in pre-Columbian Mexico, but claims of their widespread ancient use are largely exaggerated and shaped by modern idealization and ideology.[29] In 1958, the Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana. His employer, Sandoz, marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy. Increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens, but its popularity as an entheogen grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin is classified as a Schedule I controlled substance in the 1971 United Nations Convention on Psychotropic Substances.
Psilocybin is being studied as a possible medicine in the treatment of psychiatric disorders such as major depressive disorder, substance use disorders, obsessive–compulsive disorder, and other conditions such as cluster headaches.[30] Psilocybin was approved for treatment-resistant depression in Australia in 2023.[31][32] It is in late-stage clinical trials in the United States for major depressive disorder and treatment-resistant depression.[33][34][35] As of September 2026, complete submission of psilocybin for treatment-resistant depression is expected in the fourth quarter of 2026 and commercial launch for this indication is anticipated in the first half of 2027.[36][37] Especially at higher doses and combined with psychological support, single doses of psilocybin may produce rapid and long-lasting antidepressant effects that outperform placebo, though they may produce either modest or no[38] effectiveness advantage over continuous use of selective serotonin reuptake inhibitors (SSRIs) like escitalopram and trial methodological issues are common.[39][40][41][42] It can cause adverse reactions such as nausea and panic attacks.[43]
Uses
[edit]Psilocybin is used recreationally, spiritually (as an entheogen), and medically.[44] It is primarily taken orally, but other routes of administration, such as intravenous injection, are sometimes employed by licensed medical researchers using pharmaceutical-grade psilocybin powder designed for injection. Injection should never be attempted by unlicensed people.[7]
Medical
[edit]In 2023, the Therapeutic Goods Administration (TGA) approved psilocybin for treatment of treatment-resistant depression in Australia.[31][32][45] It is also under development for the treatment of depression and for various other indications elsewhere, such as the United States and Europe, but has not yet been approved in other countries (see below).[15][30][35]
In April 2026, the FDA issued a National Priority Voucher for the development of psilocybin for both major depressive disorder and treatment-resistant depression.[46] This could have allowed approval by summer 2026.[47]
Dosing
[edit]Psilocybin is used as a psychedelic at doses of 5 to 40 mg orally.[16][48] Low doses are 5 to 10 mg, an intermediate or "good effect" dose is 20 mg, and high or ego-dissolution doses are 30 to 40 mg.[16][48] Psilocybin's effects can be subjectively perceived at a dose as low as 3 mg per 70 kg body weight.[48][49] Microdosing involves the use of subthreshold psilocybin doses of less than 2.5 mg.[16][48]
When psilocybin is used in the form of psilocybin-containing mushrooms, microdoses are 0.1 g to 0.3 g and psychedelic doses are 1.0 g to 3.5–5.0 g in the case of dried mushrooms.[50][51][7] The preceding 1.0 to 5.0 g range corresponds to psilocybin doses of about 10 to 50 mg.[7] Psilocybin-containing mushrooms vary in their psilocybin and psilocin content, but are typically around 1% of the dried weight of the mushrooms (in terms of total or combined psilocybin and psilocin content).[51][52][23][7][28][53][54][55] Psilocin is about 1.4 times as potent as psilocybin because of the two compounds' difference in molecular weight.[23][56][57]
"Lemon tek" or "lemon tekking" is a method sometimes used by recreational psilocybin users.[58][59][60] It involves soaking psilocybin-containing mushrooms in citric acid-containing lemon juice to supposedly convert their psilocybin content into psilocin before administration.[58][59][60] This is claimed to hasten their onset, cause a sharper and more intense peak, and shorten their duration.[58][59][60]
Available forms
[edit]Psilocybin is most commonly consumed in the form of psilocybin-containing mushrooms, such as Psilocybe species like Psilocybe cubensis. It may also be prepared synthetically, but outside of research settings it is not typically used in this form. Regardless of form, psilocybin is usually taken orally. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing an herbal tea, or by combining with other foods to mask the bitter taste.[61] In rare cases people have intravenously injected mushroom extracts, with serious medical complications such as systemic mycological infection and hospitalization.[62][63][64][65] Another form of psilocybin (as well as of related psychedelics like 4-AcO-DMT) is mushroom edibles such as chocolate bars and gummies, which may be purchased at psychedelic mushroom stores.
Effects
[edit]
Psilocybin produces a variety of psychological, perceptual, interpersonal, and physical effects.[16]
Psychological and perceptual effects
[edit]
After ingesting psilocybin, the user may experience a wide range of emotional effects, which can include disorientation, lethargy, giddiness, euphoria, joy, and depression. In one study, 31% of volunteers given a high dose reported feelings of significant fear and 17% experienced transient paranoia.[62] In studies at Johns Hopkins University, among those given a moderate dose (but enough to "give a high probability of a profound and beneficial experience"), negative experiences were rare, whereas one-third of those given a high dose experienced anxiety or paranoia.[66][67]: 649–665 Low doses can induce hallucinatory effects. Closed-eye hallucinations may occur, where the affected person sees multicolored geometric shapes and vivid imaginative sequences.[49] Some people report synesthesia, such as tactile sensations when viewing colors.[68]: 175 At higher doses, psilocybin can lead to "intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones".[69] Open-eye visual hallucinations are common and may be very detailed, although rarely confused with reality.[49]
Psilocybin is known to strongly affect the subjective experience of the passage of time.[70][27] Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still".[71] Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred tapping rate.[71][72] These results are consistent with the drug's role in affecting prefrontal cortex activity[73] and the role that the prefrontal cortex plays in time perception,[74] but the neurochemical basis of psilocybin's effects on perception of time is not known with certainty.[75]
Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "bad trip") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. The term "bad trip" is generally used to describe a reaction characterized primarily by fear or other unpleasant emotions, not just a transitory experience of such feelings. A variety of factors may contribute to a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: set and setting). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip.[62][76] Other than the duration of the experience, the effects of psilocybin are similar to comparable doses of lysergic acid diethylamide (LSD) or mescaline. But in the Psychedelics Encyclopedia, author Peter Stafford writes: "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."[77]: 273
Set and setting and moderating factors
[edit]The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly called set and setting. In the early 1960s, Timothy Leary and his Harvard colleagues investigated the role of set and setting in psilocybin's effects. They administered the drug to 175 volunteers (from various backgrounds) in an environment intended to be similar to a comfortable living room. 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Those who had experience with psilocybin reported more pleasant experiences than those for whom the drug was novel. Group size, dose, preparation, and expectancy were important determinants of the drug response. In general, those in groups of more than eight felt that the groups were less supportive and their experiences less pleasant. Conversely, smaller groups (fewer than six) were seen as more supportive and reported more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making a user more receptive to interpersonal interactions and environmental stimuli.[78] These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dose, set, and setting are fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.[79]
Further studies demonstrate that supportive settings significantly reduce the likelihood of adverse reactions, including panic, paranoia, or psychological distress. Positive therapeutic outcomes are strongly correlated with the participant's trust in the environment and the facilitators.[80][81]
Theory of mind network and default mode network
[edit]Psychedelics, including psilocybin, have been shown to affect different clusters of brain regions known as the "theory of mind network" (ToMN) and the default mode network (DMN).[82] The ToMN involves making inferences and understanding social situations based on patterns,[83] whereas the DMN relates more to introspection and one's sense of self.[82] The DMN, in particular, is related to increased rumination and worsening self-image in patients with major depressive disorder (MDD).[84] In studies done with single use psilocybin, areas of the DMN showed decreased functional connectivity (communication between areas of the brain). This finding provides functional insight into the work of psilocybin in increasing one's sense of connection to one's surroundings, as the areas of the brain involved in introspection decrease in functionality under the effects of the drug.[85] Conversely, areas of the brain involved in the ToMN showed increased activity and functional activation in response to psychedelics. These results were not unique to psilocybin and there was no significant difference in brain activation found in similar trials of mescaline and LSD. Information and studies into the DMN and ToMN are relatively sparse and their connections to other psychiatric illnesses and the use of psychedelics is still largely unknown.[82]
Group perceptions
[edit]Through further anthropological studies regarding "personal insights"[86] and the psychosocial effects of psilocybin, it can be seen in many traditional societies that powerful mind-active substances such as psilocybin are regularly "consumed ritually for therapeutic purposes or for transcending normal, everyday reality".[87] Positive effects that psilocybin has on individuals can be observed by taking on an anthropological approach and moving away from the Western biomedical view; this is aided by the studies done by Leary.[88] Within certain traditional societies, where the use of psilocybin is frequent for shamanic healing rituals, group collectives praise their guide, healer and shaman for helping alleviate their pains, aches and hurt. They do this through a group ritual practice where the group, or just the guide, ingests psilocybin to help extract any "toxic psychic residues or sorcerous implants"[87] found in one's body.
Group therapies using "classic" psychedelics are becoming more common within clinical practice in the Western world.[89] This is speculated to grow, provided the evidence remains indicative of their safety and efficacy.[90] In social sense, the group is shaped by their experiences surrounding psilocybin and how they view the fungus collectively. As mentioned in the anthropology article,[87] the group partakes in a "journey" together, thus adding to the spiritual, social body where roles, hierarchies and gender are subjectively understood.[87]
Cultural significance and "mystical" experiences
[edit]
Psilocybin mushrooms have been and continue to be used in Indigenous American cultures in religious, divinatory, or spiritual contexts. Reflecting the meaning of the word entheogen ("the god within"), the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds. Typically used in small group community settings, they enhance group cohesion and reaffirm traditional values.[91] Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced self-awareness and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature.[92]
Psychedelic drugs can induce states of consciousness that have lasting personal meaning and spiritual significance in religious or spiritually inclined people; these states are called mystical experiences. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through non-drug techniques such as meditation or holotropic breathwork.[93][94] In the 1960s, Walter Pahnke and colleagues systematically evaluated mystical experiences (which they called "mystical consciousness") by categorizing their common features. According to Pahnke, these categories "describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations", and allow researchers to assess mystical experiences on a qualitative, numerical scale.[95]
In the 1962 Marsh Chapel Experiment, run by Pahnke at the Harvard Divinity School under Leary's supervision,[96] almost all the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences.[97] One of the participants was religious scholar Huston Smith, author of several textbooks on comparative religion; he called his experience "the most powerful cosmic homecoming I have ever experienced."[98] In a 25-year followup to the experiment, all the subjects given psilocybin said their experience had elements of "a genuine mystical nature and characterized it as one of the high points of their spiritual life".[99]: 13 Psychedelic researcher Rick Doblin considered the study partially flawed due to incorrect implementation of the double-blind procedure and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast "considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects".[99]: 24 Psychiatrist William A. Richards echoed this sentiment, writing in a 2007 review, "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry."[100]
A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure.[101] When asked in an interview about the similarity of his work to Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s."[102] Experts have praised the National Institute of Drug Abuse-funded study, published in 2006, for the soundness of its experimental design.[b] In the experiment, 36 volunteers with no experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood;[103] 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme "experience of fear" or dysphoria (i.e., a "bad trip") at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session); about one-third of these (13% of the total) reported that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject's sense of well-being.[104]
A follow-up study 14 months later confirmed that participants continued to attribute deep personal meaning to the experience. Almost a third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it was among their five most spiritually significant events. About two-thirds said the experience increased their sense of well-being or life satisfaction.[97] Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness/Intellect; personality traits are normally stable across the lifespan for adults. Likewise, in a 2010 web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.[62][105]
Physical effects
[edit]Common responses include pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions).[2][c] Psilocybin's sympathomimetic or cardiovascular effects, including increased heart rate and blood pressure, are usually mild.[44][2] On average, peak heart rate is increased by 5 bpm, peak systolic blood pressure by 10 to 15 mm Hg, and peak diastolic blood pressure by 5 to 10 mm Hg.[44][2